NCT02211079View on ClinicalTrials.gov

A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy
Interventions
DRUG

JNJ-54861911

JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.

DRUG

Caffeine

Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.

DRUG

Midazolam

Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.

DRUG

Tolbutamide

Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.

Trial Locations (1)

Unknown

Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02211079 - A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates | Biotech Hunter | Biotech Hunter